Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Psoriasis Sprays: Niche Opportunities?

Executive Summary

Expanding treatment options for psoriasis highlight how some firms are developing innovative "lower risk" assets that use established active ingredients but could provide benefits to specific patient segments.

You may also be interested in...



Dr Reddy's COO On US Derma Build-Up, One-Sided Biologics Norms

Dr Reddy's Laboratories (DRL) appears to be building on plans for its differentiated dermatology and neurology formulations in the US after gains on the approvals front.

Dr Reddy's Infuses Life Into XenoPort's Psoriasis Drug

Dr Reddy's Laboratories will take XenoPort's clinical-stage oral psoriasis NCE, XP23829, further in the US, infusing new hope in the prodrug of monomethyl fumarate (MMF) that has seen some safety issues in earlier studies and faces significant competition in the space.

To The East! Leo Pharma CEO On Global Ambitions And Astellas Buy

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel